title: Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome.
abstract: While several prognostic factors have been identified in breast carcinoma, the clinical outcome remains hard to predict for individual patients. Better predictive markers are needed to help guide difficult treatment decisions. In a previous study of 78 breast carcinoma specimens, we noted an association between poor clinical outcome and the expression of cytokeratin 17 and/or cytokeratin 5 mRNAs. Here we describe the results of immunohistochemistry studies using monoclonal antibodies against these markers to analyze more than 600 paraffin-embedded breast tumors in tissue microarrays. We found that expression of cytokeratin 17 and/or cytokeratin 5/6 in tumor cells was associated with a poor clinical outcome. Moreover, multivariate analysis showed that in node-negative breast carcinoma, expression of these cytokeratins was a prognostic factor independent of tumor size and tumor grade.
authors.affiliation: L235 Department of Pathology, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA. mrijn@stanford.edu
authors.forename: Matt
authors.initials: M
authors.lastname: van de Rijn
authors.forename: Charles M
authors.initials: CM
authors.lastname: Perou
authors.forename: Rob
authors.initials: R
authors.lastname: Tibshirani
authors.forename: Phillippe
authors.initials: P
authors.lastname: Haas
authors.forename: Olli
authors.initials: O
authors.lastname: Kallioniemi
authors.forename: Juha
authors.initials: J
authors.lastname: Kononen
authors.forename: Joachim
authors.initials: J
authors.lastname: Torhorst
authors.forename: Guido
authors.initials: G
authors.lastname: Sauter
authors.forename: Markus
authors.initials: M
authors.lastname: Zuber
authors.forename: Ossi R
authors.initials: OR
authors.lastname: Köchli
authors.forename: Frank
authors.initials: F
authors.lastname: Mross
authors.forename: Holger
authors.initials: H
authors.lastname: Dieterich
authors.forename: Rob
authors.initials: R
authors.lastname: Seitz
authors.forename: Doug
authors.initials: D
authors.lastname: Ross
authors.forename: David
authors.initials: D
authors.lastname: Botstein
authors.forename: Pat
authors.initials: P
authors.lastname: Brown
mesh_terms: D000818:Animals; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001940:Breast / Q000166:cytology / Q000378:metabolism; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053555:Keratin-5; D007633:Keratins / Q000235:genetics / Q000378:metabolism*; D009367:Neoplasm Staging; D020411:Oligonucleotide Array Sequence Analysis; D011379:Prognosis; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; C503940:KRT5 protein, human; D053555:Keratin-5; D007633:Keratins